Trial Profile
A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Acute asthma; Asthma
- Focus Therapeutic Use
- Acronyms MIRACLE
- Sponsors AstraZeneca
- 29 Aug 2023 According to an AstraZeneca media release, company will present new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the European Respiratory Society (ERS) International Congress 2023, in Milan, Italy from 9-13 September 2023
- 07 Feb 2023 Status changed from active, no longer recruiting to completed.
- 21 Mar 2022 Planned End Date changed from 17 Mar 2023 to 30 Jan 2023.